Intended for healthcare professionals


Results of the first round of a demonstration pilot of screening for colorectal cancer in the United Kingdom

BMJ 2004; 329 doi: (Published 15 July 2004) Cite this as: BMJ 2004;329:133

Without considering Oncological Terrain, cancer efficacious primary prevention and screening are not possible.


I don’t understand, once again, what accounts for the reason that
screening for colorectal cancer, e.g., by testing for faecal occult blood,
certainly feasible within the context of the United Kingdom's NHS, should
be applied to “all” people aged 50-69 years. I agree with the statement
that “Screening should lead to a reduction in deaths from colorectal
cancer in the population offered screening”, if such as screening is
performed properly, correctly and early, in individuals involved by
Oncological Terrain, and possibly by colon cancer real risk (1, 2) (See
HONCOde website 233736,

In fact, doctors must
first (i.e., before whatever research) investigate and ascertain the
presence and intensity of the Congenital Acidosic Enzyme-Acidosic
Histangiopathy (CAEMH = functional mitochindrial cytopathology) in the
"tested" population, and soon thereafter assessing prevalence and
intensity of the "Oncological Terrain", which always develops on the basis
of the above-mentioned congenital cytopathology (2, 3, 4). In fact,
without this alteration of psycho-neuro-endocrine-immunological system,
oncogenesis is not possible. Moreover, it is possible with the aid of
Biophysical Semeiotics to recognize also cancer “real risk” in the colon,
and therefore to select people in a rational matter obtaining the best
results with relatively scarse expense. This accounts for the reason that
“Planning for the EU public Health Portal” all’URL:,
suggests the SPBM (Single Patient Based Medicine, in above-cited website)
as useful tool in the primary prevention against malignancy.

conclusion, a 46-year-long clinical experience, allows me to state that
without Oncological Terrain, cancer efficacious primary prevention and
screening are not possible at all.

1) Kingdom UK Colorectal Cancer Screening Pilot Group .BMJ
2004;329:133 (17 July), doi:10.1136/bmj.38153.491887.7C (published 5 July

2) Stagnaro-Neri Marina, Stagnaro Sergio. Introduzione alla Semeiotica
Biofisica. Il Terreno oncologico”. Travel Factory SRL., Roma, 2004.

3) Stagnaro S., Stagnaro-Neri M., La Melatonina nella Terapia del Terreno
Oncologico e del “Reale Rischio” Oncologico. Ediz. Travel Factory, Roma,

4) Stagnaro-Neri M., Stagnaro S., Cancro della mammella: prevenzione
primaria e diagnosi precoce con la percussione ascoltata. Gazz. Med. It. –
Arch. Sc. Med. 152, 447 1993

Competing interests:
None declared

Competing interests: No competing interests

16 July 2004
Sergio Stagnaro
Specialist in Blood, Gastrointestinal, and Metabolic Diseases. Researcher in Biophysical Semeiotics.
Via Erasmo Piaggio 23/8 16037 Riva Trigoso (Genova) Italy.